放射治疗在胰腺癌治疗中的应用现状和展望

doi:10.16139/j.1007-9610.2022.01.007

摘要/Abstract

中图分类号:

R735.9

吴莉莉, 许耀麟, 楼文晖. 放射治疗在胰腺癌治疗中的应用现状和展望[J]. 外科理论与实践, 2022, 27(01): 25-29.

WU Lili, XU Yaolin, LOU Wenhui. Radiotherapy in management of pancreatic cancer: application and prospect[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 25-29.

参考文献 37

[1]	Cai J, Chen H, Lu M, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J]. Cancer Letters, 2021, 520:1-11. doi: 10.1016/j.canlet.2021.06.027 URL
[2]	Kalser MH, Ellenberg SS. Pancreatic cancer. adjuvant combined radiation and chemotherapy following curative resection[J]. Arch Surg, 1985, 120(8):899-903. doi: 10.1001/archsurg.1985.01390320023003 URL
[3]	Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer[J]. Cancer, 1987, 59(12):2006-2010. doi: 10.1002/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B URL
[4]	Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891[J]. Ann Surg, 2007, 246(5):734-740. pmid: 17968163
[5]	Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase Ⅲ trial of the EORTC gastrointestinal tract cancer co-operative group[J]. Ann Surg, 1999, 230(6):776-782. pmid: 10615932
[6]	Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase Ⅲ trial[J]. Ann Surg Oncol, 2011, 18(5):1319-1326. doi: 10.1245/s10434-011-1630-6 URL
[7]	Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial[J]. JAMA, 2008, 299(9):1019-1026. doi: 10.1001/jama.299.9.1019 URL
[8]	Rutter CE, Park HS, Corso CD, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the national cancer data base[J]. Cancer, 2015, 121(23):4141-4149. doi: 10.1002/cncr.29652 URL
[9]	Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study[J]. Ann Surg Oncol, 2010, 17(4):981-990. doi: 10.1245/s10434-009-0743-7 URL
[10]	Neoptolemos JP, Stocken DD, Friess H, et al. A rando-mized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med, 2004, 350(12):1200-1210. doi: 10.1056/NEJMoa032295 URL
[11]	Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial[J]. Lancet, 2001, 358(9293):1576-1585. pmid: 11716884
[12]	van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase Ⅱ study[J]. J Clin Oncol, 2010, 28(29):4450-4456. doi: 10.1200/JCO.2010.30.3446 URL
[13]	Naffouje SA, Sabesan A, Kim DW, et al. Adjuvant chemoradiotherapy in resected pancreatic ductal adenocarcinoma: where does the benefit lie? a nomogram for risk stratification and patient selection[J]. J Gastrointest Surg, 2021-09-10[online ahead of print].
[14]	Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phaseⅢ trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2):809-816. doi: 10.1016/j.ijrobp.2010.11.039 URL
[15]	中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J]. 中华外科杂志, 2021, 59(7):561-577.
[16]	Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO Clinical Practice Guideline[J]. Pract Radiat On-col, 2019, 9(5):322-332.
[17]	Khorana AA, Mangu PB, Berlin J, et al. Potentially cu-rable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(21):2541-2556. doi: 10.1200/JCO.2016.67.5553 pmid: 27247221
[18]	Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457. doi: 10.6004/jnccn.2021.0017 URL
[19]	Cohen SJ, Dobelbower RJ, Lipsitz S, et al. A randomized phaseⅢ study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Co-operative Oncology Group study E8282[J]. Int J Radiat On-col Biol Phys, 2005, 62(5):1345-1350.
[20]	The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma[J]. Ann Surg, 1979, 189(2):205-208.
[21]	Sultana A, Tudur SC, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J]. Br J Cancer, 2007, 96(8):1183-1190. doi: 10.1038/sj.bjc.6603719 URL
[22]	Huguet F, Girard N, Guerche CS, et al. Chemoradiothe-rapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review[J]. J Clin Oncol, 2009, 27(13):2269-2277. doi: 10.1200/JCO.2008.19.7921 URL
[23]	Wu L, Zhou Y, Fan Y, et al. Consolidative chemoradiotherapy after induced chemotherapy is an optimal regimen for locally advanced pancreatic cancer[J]. Front Oncol, 2019, 9:1543. doi: 10.3389/fonc.2019.01543 URL
[24]	Schneider BJ, Ben-Josef E, McGinn CJ, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2005, 63(5):1325-1330. doi: 10.1016/j.ijrobp.2005.04.030 URL
[25]	Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization[J]. Semin Oncol, 1997, 24(2 Suppl 7):S7-S24. pmid: 9194476
[26]	Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase Ⅱ chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas[J]. Int J Gastrointest Cancer, 2003, 34(2-3):107-116. pmid: 15361643
[27]	Cardenes HR, Moore AM, Johnson CS, et al. A phase Ⅱ study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study[J]. Am J Clin Oncol, 2011, 34(5):460-465. doi: 10.1097/COC.0b013e3181e9c103 URL
[28]	Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study[J]. Int J Radiat Oncol Biol Phys, 2003, 57(1):98-104. doi: 10.1016/S0360-3016(03)00435-8 URL
[29]	Brasiuniene B, Juozaityte E. The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer[J]. Medicina (Kaunas), 2007, 43(9):716-725.
[30]	Hurt CN, Falk S, Crosby T, et al. Long-term results and recurrence patterns from SCALOP: a phaseⅡ randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer[J]. Br J Cancer, 2017, 116(10):1264-1270. doi: 10.1038/bjc.2017.95 URL
[31]	Mahadevan A, Miksad R, Goldstein M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):e615-e622. doi: 10.1016/j.ijrobp.2011.04.045 URL
[32]	Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase Ⅱ and Ⅲ studies[J]. J Clin Oncol, 2007, 25(3):326-331. doi: 10.1200/JCO.2006.07.5663 URL
[33]	Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial[J]. JAMA, 2016, 315(17):1844-1853. doi: 10.1001/jama.2016.4324 URL
[34]	Perri G, Prakash L, Qiao W, et al. Response and survival associated with first-line FOLFIRINOX vs. gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma[J]. JAMA Surg, 2020, 155(9):832-839. doi: 10.1001/jamasurg.2020.2286 URL
[35]	Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant the-rapy and surgical resection[J]. Ann Surg, 2019, 270(2):340-347. doi: 10.1097/SLA.0000000000002753 pmid: 29596120
[36]	Hayashi T, Nakamura T, Kimura Y, et al. Phase 2 study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with gemcitabine for borderline resectable pancreatic adenocarcinoma(HOPS-BR 01)[J]. Int J Radiat Oncol Biol Phys, 2019, 105(3):606-617. doi: 10.1016/j.ijrobp.2019.07.004 URL
[37]	Li Y, Feng Q, Jin J, et al. Experts′ consensus on intra-operative radiotherapy for pancreatic cancer[J]. Cancer Lett, 2019, 449:1-7. doi: 10.1016/j.canlet.2019.01.038 URL

放射治疗在胰腺癌治疗中的应用现状和展望

Radiotherapy in management of pancreatic cancer: application and prospect

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[2]	朱颖, 汤玉茗, 黄佳, 章永平, 姚玮艳. 全反式维A酸可促进肿瘤相关诱导配体对多种胰腺癌细胞的凋亡作用[J]. 内科理论与实践, 2023, 18(03): 171-176.
[3]	杨盈赤, 庞凯, 张忠涛. 新辅助放疗联合免疫治疗对直肠癌微创术式应用的影响[J]. 外科理论与实践, 2023, 28(03): 186-189.
[4]	王远江, 邹浩. 胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[5]	李国立, 郭飞龙. 动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35.
[6]	何燕燕, 李凤珠. 膀胱原发性上皮样血管肉瘤一例报道及文献复习[J]. 诊断学理论与实践, 2022, 21(06): 719-725.
[7]	杨蕊馨, 杜宇童, 燕然林, 朱正纲, 李琛, 于颖彦. 消化道肿瘤单细胞转录组测序研究中生物样本前处理改良的探索[J]. 诊断学理论与实践, 2022, 21(05): 567-574.
[8]	曹璐, 郑思悦, 陈佳艺. 早期乳腺癌区域淋巴结局部处理[J]. 外科理论与实践, 2022, 27(05): 406-410.
[9]	郭杨, 郭天安, 徐烨. 直肠癌新辅助化疗的研究进展[J]. 外科理论与实践, 2022, 27(04): 370-374.
[10]	罗东凤, 游建华, 李啸扬, 李军民, 张赟翔. 不耐受强化化疗的初治老年急性髓系白血病患者诱导治疗疗效及安全性[J]. 内科理论与实践, 2022, 17(03): 220-226.
[11]	马婧嶔, 杨敏捷, 颜志平. 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133.
[12]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[13]	何敏, 刘颖斌. 可切除胰腺癌的判断标准与治疗及其争议[J]. 外科理论与实践, 2022, 27(01): 6-10.
[14]	王冲, 程石. 可切除胰腺癌术前减黄的共识与争议[J]. 外科理论与实践, 2022, 27(01): 30-33.
[15]	卫积书, 黄诗朦. 胰腺癌嗜神经侵袭与神经重塑的研究历史和治疗现状[J]. 外科理论与实践, 2022, 27(01): 42-45.